Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1662597 10.3389/fphar.2025.1662597 Pharmacology Correction Correction: Understanding the role of the gut microbiome in gastrointestinal cancer: A review Agagündüz et al. 10.3389/fphar.2025.1662597 Agagündüz Duygu 1 Cocozza Ermelinda 2 Cemali Özge 1 Bayazıt Ayşe Derya 1 Nanì Maria Francesca 3 Cerqua Ida 3 Morgillo Floriana 4 Saygılı Suna Karadeniz 5 6 Canani Roberto Berni 7 Amero Paola 5 * Capasso Raffaele 8 * 1 Department of Nutrition and Dietetics, Gazi University, Emek, Ankara, Türkiye 2 MERCK S.P.A., Rome, Italy 3 Department of Pharmacy, University of Naples “Federico II”, Naples, Italy 4 Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy 5 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States 6 Department of Histology and Embryology, Kütahya Health Sciences University, Kütahya, Türkiye 7 Department of Translational Medical Science and ImmunoNutritionLab at CEINGE Biotechnologies Research Center and Task Force for Microbiome Studies, University of Naples Federico II, Naples, Italy 8 Department of Agricultural Sciences, University of Naples Federico II, Portici, Italy

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

 *Correspondence: Raffaele Capasso, rafcapas@unina.it; Paola Amero, PAmero@mdanderson.org 30 07 2025 2025 16 1662597 09 07 2025 17 07 2025 Copyright © 2025 Agagündüz, Cocozza, Cemali, Bayazıt, Nanì, Cerqua, Morgillo, Saygılı, Canani, Amero and Capasso. 2025 Agagündüz, Cocozza, Cemali, Bayazıt, Nanì, Cerqua, Morgillo, Saygılı, Canani, Amero and Capasso

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Correction on Understanding the role of the gut microbiome in gastrointestinal cancer: A review by Ağagündüz D, Cocozza E, Cemali Ö, Bayazıt AD, Nanì MF, Cerqua I, Morgillo F, Saygılı SK, Berni Canani R, Amero P and Capasso R (2023). Front. Pharmacol. 14:1130562. doi: 10.3389/fphar.2023.1130562 microbiome gastrointestinal cancer non-coding RNAs therapeutics diagnosis section-at-acceptance Gastrointestinal and Hepatic Pharmacology

In the published article, an incorrect Funding statement was provided. The corrected Funding statement appears below.

The original article has been updated.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. The paper was funded under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 1.3—Call for tender No. 341 of 15 March 2022 of Italian Ministry of University and Research funded by the European Union—NextGenerationEU. Project code PE00000003, Concession Decree No. 1550 of 11 October 2022, adopted by the Italian Ministry of University and Research, CUP E63C22002030007, Project title “ON Foods—Research and innovation network on food and nutrition Sustainability, Safety and Security—Working ON Foods.”

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.